PCM
CSTL icon

Prelude Capital Management’s Castle Biosciences CSTL Stock Holding History

Prelude Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,193
Closed -$263K – 1353
2023
Q4 		$263K Buy
+12,193
New +$215K 0.02% 803
2023
Q2 		– Sell
-23,144
Closed -$526K – 1167
2023
Q1 		$526K Hold
23,144
– – 0.03% 448
2022
Q4 		$545K Hold
23,144
– – 0.03% 537
2022
Q3 		$604K Buy
23,144
+86
+0.4% +$2.41K 0.02% 578
2022
Q2 		$506K Buy
23,058
+15,591
+209% +$362K 0.01% 805
2022
Q1 		$335K Buy
7,467
+1,612
+28% +$66.6K 0.01% 1029
2021
Q4 		$251K Buy
5,855
+707
+14% +$36.9K 0.01% 1424
2021
Q3 		$342K Buy
5,148
+5
+0.1% +$352 0.01% 1071
2021
Q2 		$377K Buy
+5,143
New +$340K 0.01% 1090
2020
Q1 		– Sell
-24,101
Closed -$828K – 1526
2019
Q4 		$828K Hold
24,101
– – 0.03% 443
2019
Q3 		$436K Buy
+24,101
New +$534K 0.02% 556

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Prelude Capital Management's CSTL Position: Q1 2024 in Review

Prelude Capital Management sold out of Castle Biosciences (CSTL) in Q1 2024, closing a stake of 12,193 shares — an estimated $263K sold.

Prelude Capital Management first reported a position in CSTL in Q3 2019 and held it in 11 quarters. The position peaked at $828K in Q4 2019. 151 funds tracked by Wall St. Rank hold CSTL as of Q1 2024.

  • Prelude Capital Management reported no remaining Castle Biosciences position as of Q1 2024 after selling out during the quarter.
  • Prelude Capital Management sold 12,193 Castle Biosciences shares in Q1 2024, an estimated $263K.
  • Prelude Capital Management first reported a position in Castle Biosciences in Q3 2019 and held it in 11 quarters.
  • Prelude Capital Management's Castle Biosciences position peaked at $828K in Q4 2019.
  • 151 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.